Does the Order in Which Vaccines Are Administered Affect Pain Response?
NCT00390130 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2013-11-13
Summary
The objective of this study is to determine whether there should be a predetermined sequence recommended for administering these two vaccines, with the less painful vaccine being given first.
Conditions
Interventions
- DRUG
-
Pentacel (DPTaP+Hib)
- DRUG
-
Prevnar (conjugated pneumococcal vaccine)
Sponsors & Collaborators
-
The Hospital for Sick Children
lead OTHER
Principal Investigators
-
Moshe Ipp, MD · The Hospital for Sick Children, Toronto Canada
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 2 Months
- Max Age
- 6 Months
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-07-31
- Primary Completion
- 2007-06-30
- Completion
- 2008-07-31
Countries
- Canada
Study Locations
More Related Trials
-
Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time
NCT00581035 ·Status: COMPLETED ·Phase: PHASE4
-
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
NCT03313037 ·Status: COMPLETED ·Phase: PHASE2
-
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
NCT02124161 ·Status: COMPLETED ·Phase: PHASE4
-
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
NCT04379713 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)
NCT02225587 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants
NCT03550313 ·Status: TERMINATED ·Phase: PHASE2
-
Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines
NCT01432158 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00384059 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
NCT03512288 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
NCT04887948 ·Status: COMPLETED ·Phase: PHASE3
-
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326 ·Status: COMPLETED ·Phase: PHASE3
-
Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration
NCT00758264 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
NCT00824655 ·Status: COMPLETED ·Phase: PHASE3
-
Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
NCT01392378 ·Status: COMPLETED ·Phase: PHASE4
-
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
NCT00574548 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
NCT00521586 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
NCT00427895 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination
NCT03835975 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years
NCT02955160 ·Status: COMPLETED ·Phase: PHASE1
-
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
NCT04546425 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00366899 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
NCT00761631 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
NCT06182124 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
NCT00307567 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)
NCT00169507 ·Status: COMPLETED ·Phase: PHASE3